On Wednesday, Shares of Noble Corporation plc (NYSE:NE), lost -3.01% to $14.81.
Noble Corporation, declared it plans to report financial results for the second quarter 2015 on Wednesday, July 29, 2015, after the close of trading on the New York Stock Exchange.
Noble also has planned a conference call and webcast related to its second quarter 2015 results on Thursday, July 30, 2015, at 8:00 a.m. U.S. Central Daylight Time. Interested parties are invited to listen to the call by dialing 1-866-461-7129, or internationally 1-706-679-3084, using access code: 61268886, or by asking for the Noble Corporation conference call. Interested parties may also listen over the Internet through a link posted in the Investor Relations section of the Company’s Web site.
Noble Corporation plc operates as an offshore drilling contractor for the oil and gas industry worldwide. It owns and operates a fleet of mobile offshore drilling units. As of December 31, 2014, the company operated a fleet of 15 jackups, 9 drillships, and 8 semisubmersibles, counting 1 high-specification, harsh environment jackup under construction.
Shares of Jack in the Box Inc. (NASDAQ:JACK), inclined -0.74% to $88.89, during its last trading session.
Jack in the Box, declared completion of an amendment to its existing senior credit facility. Under the terms of the amendment, the credit facility was raised to $1.2 billion, which comprises of a $300 million term loan and $900 million revolving credit facility.
Following the amendment on July 1, 2015, $300 million was outstanding on the term loan and about $382 million was drawn or used for letters of credit under the revolving credit facility.
There was no change to the maturity date or interest rates for either facility. The maturity date for both the revolving credit facility and the term loan will remain in March 2019. The interest rate on the senior credit facility is based on the company’s leverage ratio and can range from LIBOR plus 1.25 percent to 2.00 percent. The interest rate as of the date of the amendment was LIBOR plus 1.75 percent.
The amendment also raised the maximum leverage ratio from 3.0 times to 3.5 times, permits unlimited restricted payments if pro forma leverage is less than 3.0 times (from 2.75 times formerly), subject to pro forma fixed charge covenant compliance, and eliminates the annual limitation on capital expenditures.
Jack in the Box Inc. operates and franchises Jack in the Box quick-service restaurants and Qdoba Mexican Grill fast-casual restaurants in the United States.
Finally, Synta Pharmaceuticals Corp. (NASDAQ:SNTA), ended its last trade with -4.44% loss, and closed at $2.15.
Synta Pharmaceuticals, declared the publication in this month’s issue of Cancer Immunology Research of an in-depth review describing the rationale for pursuing the combination of Hsp90 and immune checkpoint inhibition for cancer therapy. The review article, titled “Targeting Heat-Shock Protein 90 (Hsp90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy,” is accessible online at http://cancerimmunolres.aacrjournals.org. Synta is presently studying the Hsp90 inhibitor ganetespib in several randomized studies, counting the GALAXY-2 trial, a global, randomized, multi-center Phase 3 study of ganetespib and docetaxel for the second-line treatment of advanced non-small cell lung adenocarcinoma.
The review article describes preclinical findings that suggest that proteasomal degradation of cellular client proteins associated with Hsp90 inhibition may augment antitumor immune response through raised cellular antigen expression and subsequent improved T-cell recruitment and tumor-cell recognition. The review article also explains that client proteins affected by Hsp90 inhibition comprise oncogenes that may drive expression of Programmed Death-Ligand 1 (PD-L1), a key immune checkpoint. The resulting reduction of PD-L1 expression on tumor cells may enhance T-cell mediated cytotoxic activity and complement the activity of selective anti-PD-1 or anti-PD-L1 antibody therapies. This is supported by in vivo study results, where ganetespib was found to potentiate the antitumor efficacy of anti-PD-L1 antibody treatment. In these studies, the combination of ganetespib and an anti-PD-L1 antibody displayed significantly greater antitumor activity than either individual agent, in mouse models of both colon carcinoma and melanoma.
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
